tbuckley/cabot-search huggingface dataset:
Abstract 12607: Improvement in Skin Inflammation Associates With Improvement in Aortic Vascular Inflammation by 18-FDG PET/CT in Psoriasis
Authors: Amit K Dey, Joseph B Lerman, Tsion M Aberra, Abhishek Chaturvedi, Mohammad T Kabbany, Aditya A Joshi, Justin A Rodante, Joanna I Silverman, Asha Dahiya, Parag Shukla, Balaji Natarajan, Heather L Teague, Taufiq Salahuddin, Qimin Ng, Tarek Z Aridi, Martin P Playford, Benjamin N Lockshin, Mark A Ahlman, Marcus Y Chen, Joel M Gelfand, Nehal N Mehta
Journal: Circulation (2016)

Introduction: Inflammation is a risk factor for the initiation and progression of atherosclerosis. Psoriasis (PSO), a chronic inflammatory skin disease, is an emerging risk factor for cardiovascular (CV) disease. Indeed PSO severity is associated with increased vascular inflammation (VI) by 18-FDG PET/CT in vivo and with future CV risk. However, the longitudinal impact of changes in PSO severity on vascular disease is unknown. Hypothesis: We hypothesized that an improvement in PSO severity would associate with an improvement in VI by FDG PET/CT. Methods: Consecutively recruited PSO patients (N=102) underwent FDG PET/CT scans, and cardiometabolic profiling at baseline and 1-year. VI was assessed as target-to-background ratio (TBR) (Excellence Brilliant Workstation). PSO severity was measured as Psoriasis Area Severity Index (PASI) score. The longitudinal change in VI of the aortic arch was analyzed using unadjusted and adjusted multivariable regression. Results: The cohort was middle-aged, had a low CV risk by Framingham risk score and had mild to moderate PSO severity. At follow-up, patients had a median improvement in PASI score of 31.91% (p&lt;0.001) with use of topical (67%), biological (62%) and UVB (16%) therapy. Aortic TBR in these patients improved (6.3%, p&lt;0.001) (Table 1). Improvement in PASI score associated with an improvement in aortic arch TBR beyond adjustment for traditional CV risk factors, statin use, &amp; systemic/biologic PSO therapy (β=0.21, p = 0.03). Conclusions: Improvement in PSO severity associated with an improvement in aortic VI by FDG PET/CT, suggesting that skin inflammation may present a modifiable risk factor to mitigate CV risk. This finding of a 6.3% decrease in VI with improvement in PASI score is of similar magnitude to that observed after low-dose statin therapy in coronary artery disease, suggesting control of remote inflammation may quell vascular disease progression. Larger studies are needed to confirm these findings.
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
Authors: Livius Penter, Yi Zhang, Alexandra Savell, Teddy Huang, Nicoletta Cieri, Emily M. Thrash, Seunghee Kim-Schulze, Aashna Jhaveri, Jingxin Fu, Srinika Ranasinghe, Shuqiang Li, Wandi Zhang, Emma S. Hathaway, Matthew Nazzaro, Haesook T. Kim, Helen Chen, Magdalena Thurin, Scott J. Rodig, Mariano Severgnini, Carrie Cibulskis, Stacey Gabriel, Kenneth J. Livak, Corey Cutler, Joseph H. Antin, Sarah Nikiforow, John Koreth, Vincent T. Ho, Philippe Armand, Jerome Ritz, Howard Streicher, Donna Neuberg, F. Stephen Hodi, Sacha Gnjatic, Robert J. Soiffer, X. Shirley Liu, Matthew S. Davids, Pavan Bachireddy, Catherine J. Wu
Journal: Blood (2021)
Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer
Authors: Susan Tweedie, Elspeth Bruford, Herman Yeger, David Brigstock, Gary Fisher, Lester Lau, James Hutchenreuther, Krista Vincent, Chris Norley, Michael Racanelli, Stephen Gruber, Timothy Johnson, Douglas Fullen, Leon Raskin, David Holdsworth, Lynne-Marie Postovit, Andrew Leask, Vinay Pasupuleti, Xingjian Hu, Wenconghui Wu, Shitong Shi, Haneen Mohammad, Philip Klenotic, Yvonne Dombrowski, Thomas O'Hagan, Marie Dittmer, Rosana Penalva, Sonia Mayoral, Peter Bankhead, Samara Fleville, George Eleftheriadis, Chao Zhao, Michelle Naughton, Rachel Hassan, Jill Moffat, John Falconer, Amanda Boyd, Peter Hamilton, Ingrid Allen, Adrien Kissenpfennig, Paul Moynagh, Emma Evergren, Anna Williams, Rebecca Ingram, Jonah Chan, Robin Franklin, Denise Fitzgerald, Ka-Wing Fong, Jonathan Zhao, Jung Kim, Shangze Li, Yeqing Yang, Bing Song, Laure Rittie, Ming Hu, Ximing Yang, Jindan Yu, Chao Zhang, Dustin van der Voort, Hong Shi, Rongli Zhang, Yulan Qing, Shuichi Hiraoka, Minoru Takemoto, Koutaro Yokote, Joseph Moxon, Paul Norman, Helena Kuivaniemi, G. Brandon Atkins, Stanton Gerson, Guo-Ping Shi, Jonathan Golledge, Nianguo Dong, Bernard Perbal, Domenick Prosdocimo, Zhiyong Lin
Journal: Journal of Clinical Investigation (2016)
OA07.09 Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints
Authors: B. Han, T. Chu, R. Zhong, H. Zhong, B. Zhang, W. Zhang, C. Shi, J. Qian, Y. Zhang, Q. Chang, X. Zhang, Y. Dong, J. Teng, Z. Gao, H. Qiang, W. Nie, Y. Zhao, Y. Han, Y. Chen
Journal: Journal of Thoracic Oncology (2021)
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension
Authors: Xiaoxuan Liu, Samantha Cruz Rivera, David Moher, Melanie J Calvert, Alastair K Denniston, Hutan Ashrafian, Andrew L Beam, An-Wen Chan, Gary S Collins, Ara DarziJonathan J Deeks, M Khair ElZarrad, Cyrus Espinoza, Andre Esteva, Livia Faes, Lavinia Ferrante di Ruffano, John Fletcher, Robert Golub, Hugh Harvey, Charlotte Haug, Christopher Holmes, Adrian Jonas, Pearse A Keane, Christopher J Kelly, Aaron Y Lee, Cecilia S Lee, Elaine Manna, James Matcham, Melissa McCradden, Joao Monteiro, Cynthia Mulrow, Luke Oakden-Rayner, Dina Paltoo, Maria Beatrice Panico, Gary Price, Samuel Rowley, Richard Savage, Rupa Sarkar, Sebastian J Vollmer, Christopher Yau
Journal: The Lancet Digital Health (2020)

The CONSORT 2010 statement provides minimum guidelines for reporting randomised trials. Its widespread use has been instrumental in ensuring transparency in the evaluation of new interventions. More recently, there has been a growing recognition that interventions involving artificial intelligence (AI) need to undergo rigorous, prospective evaluation to demonstrate impact on health outcomes. The CONSORT-AI (Consolidated Standards of Reporting Trials-Artificial Intelligence) extension is a new reporting guideline for clinical trials evaluating interventions with an AI component. It was developed in parallel with its companion statement for clinical trial protocols: SPIRIT-AI (Standard Protocol Items: Recommendations for Interventional Trials-Artificial Intelligence). Both guidelines were developed through a staged consensus process involving literature review and expert consultation to generate 29 candidate items, which were assessed by an international multi-stakeholder group in a two-stage Delphi survey (103 stakeholders), agreed upon in a two-day consensus meeting (31 stakeholders), and refined through a checklist pilot (34 participants). The CONSORT-AI extension includes 14 new items that were considered sufficiently important for AI interventions that they should be routinely reported in addition to the core CONSORT 2010 items. CONSORT-AI recommends that investigators provide clear descriptions of the AI intervention, including instructions and skills required for use, the setting in which the AI intervention is integrated, the handling of inputs and outputs of the AI intervention, the human-AI interaction and provision of an analysis of error cases. CONSORT-AI will help promote transparency and completeness in reporting clinical trials for AI interventions. It will assist editors and peer reviewers, as well as the general readership, to understand, interpret, and critically appraise the quality of clinical trial design and risk of bias in the reported outcomes.
Abstract 12552: Beta Blocker and Renin-angiotensin System Inhibitors Are Associated With Decreased Mortality in Patients With Left Ventricular Assist Devices
Authors: Zeina Jedeon, Rebecca Cogswell, Jessica Schultz, Ranjit John, Henri Roukoz
Journal: Circulation (2019)

Background: Beta-blockers (BB) and renin-angiotensin system inhibitors (RASi) are proven to decrease mortality in patients with heart failure. The association between the use of BB and RASi and mor...
P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System
Authors: D. Hao, J. Laskin, S. Laurie, J. Agulnik, R. Juergens, D. Ezeife, J. Law, L. Le, L. Kiedrowski, B. Melosky, F. Shepherd, V. Cohen, R. Vandermeer, A. Shokoohi, J. Li, R. Fernandes, R. Lanman, N. Leighl
Journal: Journal of Thoracic Oncology (2021)
Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation
Authors: Zih-Chan Lin, Tsong-Long Hwang, Tse-Hung Huang, Kohei Tahara, Jiří Trousil, Jia-You Fang
Journal: Theranostics (2021)

To improve the treatment of psoriasiform inflammation, we developed actively targeted nanocarriers loaded with the phosphodiesterase 4 inhibitor AN2728. Methods: Phospholipid-poly(lactic-co-glycolic acid) nanohybrids were prepared and conjugated with monovalent anti-desmoglein 3 antibody to bind keratinocytes. Results: The actively targeted nanohybrids were 229 nm in mean size with a nearly neutral surface charge. Flow cytometry and confocal microscopy showed a 9-fold increase in keratinocyte uptake of targeted nanohybrids relative to non-targeted nanoparticles. The nanoparticles localized mainly in lysosomes after internalization. AN2728-loaded antibody-conjugated nanocarriers inhibited cytokine/chemokine overexpression in activated keratinocytes without affecting cell viability. The targeted nanohybrids also suppressed neutrophil migration by reducing CXCL1 and CXCL2 release from keratinocytes. Following subcutaneous administration in mice, the nanohybrids distributed to the epidermis and hair follicles. In a psoriasis-like skin mouse model, the actively targeted nanoparticles were superior to free drug and non-targeted nanoparticles in mitigating skin inflammation. Intervention with the targeted nanosystem reduced the epidermal thickness of the psoriasiform lesion from 191 to 42 µm, decreased the Psoriasis Area Severity Index by 74%, restored barrier function, and returned chemokine levels to baseline. Conclusions: Our developed nanosystem was safe and demonstrated efficient targeting properties for the treatment of cutaneous inflammation.
P84.11 Real-World Brigatinib Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in the United States
Authors: H. Lin, Y. Wu, M. Gorritz, C. Mcguiness, W. Huang, C. Chen, K. Ren, R. Camidge
Journal: Journal of Thoracic Oncology (2021)
Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC
Authors: Shanying Gui, W Quinn O'Neill, Theodoros N Teknos, Quintin Pan
Journal: Journal for ImmunoTherapy of Cancer (2021)

Patients with human papillomavirus (HPV+) head and neck squamous cell carcinoma (HNSCC) have superior prognoses compared with patients with HPV- HNSCC and strategies for treatment de-escalation are under investigation for the HPV+ setting. However, the survival advantage associated with HPV is not universal, and a subset of patients with HPV+ HNSCC fail definitive treatment and progress with metastatic/recurrent disease. Currently, no biomarker is available to distinguish aggressive from indolent HPV+ HNSCC. Immune dysfunction facilitates tumorigenesis and is associated with poor treatment response; therefore, we hypothesized that diminished intratumoral immune cell functionality may be attractive biomarkers to identify patients with HPV+ HNSCC at risk for early disease-specific mortality.This is a retrospective analysis of The Cancer Genome Atlas (TCGA) HPV+ HNSCC cohort.Immunoglobulin J polypeptide (IGJ), uniquely expressed in plasma cells, showed a broad expression range in HPV+ HNSCC. Cox regression model, adjusting for clinical covariates, indicated that IGJ is an independent prognostic biomarker for disease-specific survival (DSS) and overall survival (OS). Patients with low IGJ had a 7.2-fold (p<0.001) increase in risk of disease-specific death with a median DSS of 13 months. Low IGJ showed an area under curve (AUC) of 0.89 with 91.0% sensitivity and 87.6% specificity to identify early disease-specific mortality (defined as DSS ≤12 months). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed a global dampening of immune pathways in low IGJ tumors.Our work showed that IGJ is a robust and independent prognostic biomarker for disease-specific mortality in HPV+ HNSCC. Patient with HPV+ HNSCC with limited adaptive immune functionality should not be candidates for treatment de-escalation modalities.
Racial Equity in Crisis Standards of Care—Reassuring Data or Reason for Concern?
Authors: Emily C. Cleveland Manchanda, Melanie F. Molina, Robert M. Rodriguez
Journal: JAMA Network Open (2021)

Hayley B. Gershengorn, MD; Gregory E. Holt, MD, PhD; Andrew Rezk, BS; Stefanie Delgado, BS; Nayna Shah, BA; Arshia Arora, BS; Leah B. Colucci, MS; Belen Mora, BS, BA; Rahul S. Iyengar, MHA; Andy Lopez, MS; Bianca M. Martinez, BS; Joseph West, ScM, ScD; Kenneth W. Goodman, PhD; Daniel H. Kett, MD; Jeffrey P. Brosco, MD, PhD
Covid-19: variants and vaccination
Authors: Alistair C Darby, Julian A Hiscox
Journal: BMJ (2021)

<h3>Background</h3> Tablet splitting can provide dose flexibility and cost savings; however, pharmaceutical representatives typically discourage the practice. <h3>Aim</h3> To identify and summarise all published concerns related to tablet splitting and to present the experimental evidence that investigates those concerns. <h3>Design &amp; setting</h3> Systematic review and qualitative synthesis of tablet-splitting concerns and evidence. <h3>Method</h3> Medline and EMBASE databases were searched over all years of publication for articles in English discussing the splitting of tablets. Eligible articles included original research, narrative reviews, systematic reviews, and expert opinion. <h3>Results</h3> After removing duplicates, 1837 potentially relevant articles underwent dual review, whereupon 1612 articles were excluded based on title and abstract. After examination of 225 full texts, 138 articles were included (one systematic review, four narrative reviews, 101 original research articles, and 32 opinion articles). The described concerns included difficulty breaking tablets, loss of mass, weight variability, chemical instability, overly rapid dosing if sustained-release medications are split, non-compliance, and patient confusion resulting in medication errors. No substantive evidence was found to support concerns regarding loss of mass, weight variability, chemical instability, or non-compliance. Evidence does support some older adults struggling to split tablets without tablet splitters, and the inappropriateness of splitting sustained-release preparations, given the potential for alteration of the rate of drug release for some products. <h3>Conclusion</h3> With the exception of sustained-release tablets, which should not be split, and excepting those older people who may struggle to split tablets based on physical limitations, there is little evidence to support tablet-splitting concerns.
BPI21-004: A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States
Authors: Petros Grivas, Meaghan Roach, Vivek Pawar, Caroline Huber, Suepattra May-Slatter, Isha Desai, Jane Chang, Murtuza Bharmal
Journal: Journal of the National Comprehensive Cancer Network (2021)

"BPI21-004: A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States" published on 17 Mar 2021 by National Comprehensive Cancer Network.
Brain network reorganisation in an adolescent after bilateral perinatal strokes
Authors: Timothy O Laumann, Mario Ortega, Catherine R Hoyt, Nicole A Seider, Abraham Z Snyder, Nico UF Dosenbach, Joshua S. Siegel, Annie L. Nguyen, Donna L. Dierker, Rebecca S. Coalson, Babatunde Adeyemo, Scott Marek, Adrian W. Gilmore, Steven M. Nelson, Joshua S. Shimony, Deanna J. Greene, Marcus E. Raichle, Evan M. Gordon, Steven E. Petersen, Bradley L. Schlaggar
Journal: The Lancet Neurology (2021)
Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction
Authors: Pragyi Shrestha, Saritha Adepu, Romain R. Vivès, Rana El Masri, Astrid Klooster, Fleur Kaptein, Wendy Dam, Stephan J. L. Bakker, Harry van Goor, Bart van de Sluis, Jacob van den Born
Journal: Journal of the American Society of Nephrology (2021)

Significance Statement Hypertension and elevated levels of LDL cholesterol (LDLc) are vital risk factors for cardiovascular disease (CVD) in patients with CKD. Although statins indisputably reduce plasma cholesterol levels, not all patients with renal disease benefit from them, making CVD the leading cause of CKD-related mortality. CKD induces hyperelongation of hepatic heparan sulfate (HS) chains from HS proteoglycans (HSPG), thereby increasing the HSPG–proprotein convertase subtilisin kexin type-9 (PCSK9) interaction. These changes associate with elevated LDLc levels, without affecting LDL-receptor expression. This study, using rat models, discloses a novel mechanism behind hypercholesterolemia in CKD with prospects for future investigation of the HSPG-PCSK9 interaction and development of novel heparin-related glycomimetics targeting interruption of HSPG-PCSK9 binding. Background Dyslipidemia is an important risk factor in CKD. The liver clears triglyceride-rich lipoproteins (TRL) via LDL receptor (LDLR), LDLR-related protein-1 (LRP-1), and heparan sulfate proteoglycans (HSPGs), mostly syndecan-1. HSPGs also facilitate LDLR degradation by proprotein convertase subtilisin/kexin type 9 (PCSK9). Progressive renal failure affects the structure and activity of hepatic lipoprotein receptors, PCSK9, and plasma cholesterol. Methods Uninephrectomy- and aging-induced CKD in normotensive Wistar rats and hypertensive Munich-Wistar-Frömter (MWF) rats. Results Compared with 22-week-old sex- and strain-matched rats, 48-week-old uninephrectomized Wistar-CKD and MWF-CKD rats showed proteinuria, increased plasma creatinine, and hypercholesterolemia (all P &lt;0.05), which were most apparent in hypertensive MWF-CKD rats. Hepatic PCSK9 expression increased in both CKD groups ( P &lt;0.05), with unusual sinusoidal localization, which was not seen in 22-week-old rats. Heparan sulfate (HS) disaccharide analysis, staining with anti-HS mAbs, and mRNA expression of HS polymerase exostosin-1 ( Ext-1 ), revealed elongated HS chains in both CKD groups. Solid-phase competition assays showed that the PCSK9 interaction with heparin-albumin (HS-proteoglycan analogue) was critically dependent on polysaccharide chain length. VLDL binding to HS from CKD livers was reduced ( P &lt;0.05). Proteinuria and plasma creatinine strongly associated with plasma cholesterol, PCSK9, and HS changes. Conclusions Progressive CKD induces hepatic HS elongation, leading to increased interaction with PCSK9. This might reduce hepatic lipoprotein uptake and thereby induce dyslipidemia in CKD. Therefore, PCSK9/HS may be a novel target to control dyslipidemia.
Estimated Effect on Life Expectancy of Alleviating Primary Care Shortages in the United States
Authors: Sanjay Basu, Russell S. Phillips, Seth A. Berkowitz, Bruce E. Landon, Asaf Bitton, Robert L. Phillips
Journal: Annals of Internal Medicine (2021)

Background: Prior studies have reported that greater numbers of primary care physicians (PCPs) per population are associated with reduced population mortality, but the effect of increasing PCP density in areas of low density is poorly understood. Objective: To estimate how alleviating PCP shortages might change life expectancy and mortality. Design: Generalized additive models, mixed-effects models, and generalized estimating equations. Setting: 3104 U.S. counties from 2010 to 2017. Participants: Children and adults. Measurements: Age-adjusted life expectancy; all-cause mortality; and mortality due to cardiovascular disease, cancer, infectious disease, respiratory disease, and substance use or injury. Results: Persons living in counties with less than 1 physician per 3500 persons in 2017 had a mean life expectancy that was 310.9 days shorter than for persons living in counties above that threshold. In the low-density counties (n = 1218), increasing the density of PCPs above the 1:3500 threshold would be expected to increase mean life expectancy by 22.4 days (median, 19.4 days [95% CI, 0.9 to 45.6 days]), and all such counties would require 17 651 more physicians, or about 14.5 more physicians per shortage county. If counties with less than 1 physician per 1500 persons (n = 2636) were to reach the 1:1500 threshold, life expectancy would be expected to increase by 56.3 days (median, 55.6 days [CI, 4.2 to 105.6 days]), and all such counties would require 95 754 more physicians, or about 36.3 more physicians per shortage county. Limitation: Some projections are based on extrapolations of the actual data. Conclusion: In counties with fewer PCPs per population, increases in PCP density would be expected to substantially improve life expectancy. Primary Funding Source: None.
P04.03 Patient Characteristics and Clinical Outcomes of Stage III NSCLC in a Real-World Setting: KINDLE Korean Subset Data.
Authors: B.C. Cho, S. Kim, S.S. Lee, H.S. Park, H.K. Ahn, H.W. Lee, S.M. Lim, J. Kim, J.Y. Lim, J. Han
Journal: Journal of Thoracic Oncology (2021)
TRVD Therapy in Acute HF
Authors: Marc Vanderheyden, Jozef Bartunek, Aleksandar N. Neskovic, Davor Milicic, Joelle Keffer, Srdjan Kafedzic, Hrvoje Jurin, Nicolas Borenstein, Wilfried Mullens, Ehud Schwammenthal
Journal: Journal of the American College of Cardiology (2021)